Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.

Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, Nobori T, Ito M.

J Cardiol. 2012 Dec;60(6):462-9. doi: 10.1016/j.jjcc.2012.09.002. Epub 2012 Oct 12.

2.

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.

Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M.

J Am Coll Cardiol. 2008 Nov 4;52(19):1540-5. doi: 10.1016/j.jacc.2008.08.013.

3.

Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.

Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK.

J Card Fail. 2011 Dec;17(12):982-9. doi: 10.1016/j.cardfail.2011.08.012. Epub 2011 Oct 6.

PMID:
22123359
4.

Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.

Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.

Biochem Pharmacol. 2008 Mar 15;75(6):1322-30. doi: 10.1016/j.bcp.2007.11.011. Epub 2007 Dec 3.

PMID:
18179782
5.

Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.

Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S67-76. doi: 10.1007/s10557-011-6350-4.

PMID:
22120095
6.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA.

Circulation. 2001 Nov 13;104(20):2417-23.

7.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

8.

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.

Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators.

J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22. doi: 10.2459/JCM.0b013e328355a740.

PMID:
22673023
9.

Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.

Rauch B, Zimmermann R, Kapp M, Haass M, Von Molitor S, Smolarz A, Neumann FJ, Kübler W, Dietz R, Tillmanns H.

Clin Cardiol. 1991 May;14(5):386-95.

10.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
11.

Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.

Sato Y, Dohi K, Watanabe K, Tanimura M, Takeuchi T, Sugiura E, Sugimoto T, Kumagai N, Ogura T, Nakamori S, Fujimoto N, Yamada N, Ito M.

Int Heart J. 2016;57(2):211-9. doi: 10.1536/ihj.15-330. Epub 2016 Mar 11.

12.

A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.

Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O'Brien T, Zimmer C, Orlandi C, Konstam MA.

J Card Fail. 2011 Dec;17(12):973-81. doi: 10.1016/j.cardfail.2011.08.005. Epub 2011 Sep 9.

PMID:
22123358
13.

Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.

Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, de Voogd H, Böcker C, Ziegler D, Godes M, Nakov R, Essers H, Verboom C, Hocher B.

Circ Heart Fail. 2009 Nov;2(6):523-31. doi: 10.1161/CIRCHEARTFAILURE.108.798389. Epub 2009 Sep 24.

14.

Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure.

Wimmer A, Stanek B, Kubecova L, Vitovec J, Spinar J, Yilmaz N, Kos T, Hartter E, Frey B, Pacher R.

Jpn Heart J. 1999 May;40(3):321-34.

15.

Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure.

Münzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, Drexler H.

Circulation. 1992 Oct;86(4):1089-98.

PMID:
1394917
16.

Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.

Hülsmann M, Stanek B, Frey B, Berger R, Rödler S, Siegel A, Hartter E, Schuller M, Ogris E, Pacher R.

J Heart Lung Transplant. 1997 May;16(5):556-62.

PMID:
9171275
17.

Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.

Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, Shiota M, Hanatani A, Shimada K, Iwao H, Yoshiyama M.

Circ Heart Fail. 2012 Nov;5(6):794-802. doi: 10.1161/CIRCHEARTFAILURE.112.968750. Epub 2012 Sep 14.

18.

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure.

Kukin ML, Freudenberger RS, Mannino MM, Kalman J, Steinmetz M, Buchholz-Varley C, Ocampo ON.

Am Heart J. 1999 Aug;138(2 Pt 1):261-8.

PMID:
10426837
19.

Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.

Schroth M, Plank C, Meissner U, Eberle KP, Weyand M, Cesnjevar R, Dötsch J, Rascher W.

Pediatrics. 2006 Jul;118(1):e76-84. Epub 2006 Jun 2.

PMID:
16751617
20.

Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure.

Serizawa T, Hirata Y, Kohmoto O, Iizuka M, Matsuoka H, Sato H, Takahashi T, Mochizuki T, Ishii M, Sugimoto T, et al.

Jpn Heart J. 1988 Mar;29(2):143-9.

PMID:
2969428

Supplemental Content

Support Center